Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

  1. Cabrero, M.
  2. Martin, A.
  3. Briones, J.
  4. Gayoso, J.
  5. Jarque, I.
  6. López, J.
  7. Grande, C.
  8. Heras, I.
  9. Arranz, R.
  10. Bernal, T.
  11. Perez-Lopez, E.
  12. López-Godino, O.
  13. Conde, E.
  14. Caballero, D.
Aldizkaria:
Biology of Blood and Marrow Transplantation

ISSN: 1523-6536,  1083-8791

Argitalpen urtea: 2017

Alea: 23

Zenbakia: 1

Orrialdeak: 53-59

Mota: Artikulua

DOI: 10.1016/J.BBMT.2016.10.003 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak